



(86) Date de dépôt PCT/PCT Filing Date: 2007/07/12
 (87) Date publication PCT/PCT Publication Date: 2009/01/15
 (85) Entrée phase nationale/National Entry: 2010/01/07
 (86) N° demande PCT/PCT Application No.: US 2007/073408
 (87) N° publication PCT/PCT Publication No.: 2009/008890

(51) Cl.Int./Int.Cl. *A61K 31/381* (2006.01),
A61P 25/28 (2006.01)
 (71) Demandeur/Applicant:
ACUMEN PHARMACEUTICALS, INC., US
 (72) Inventeurs/Inventors:
KRAFFT, GRANT A., US;
PRAY, TODD, US;
GOURE, WILLIAM F., US
 (74) Agent: RIDOUT & MAYBEE LLP

(54) Titre : PROCÉDES DE MODIFICATION D'OLIGOMERES AMYLOIDES β AU MOYEN DE COMPOSES NON PEPTIDIQUES

(54) Title: METHODS OF MODIFYING AMYLOID β OLIGOMERS USING NON-PEPTIDIC COMPOUNDS




FIG.1

(57) Abrégé/Abstract:

Disclosed are methods of inhibiting, regulating, and/or modulating the formation of soluble, globular, non-fibrillar, neurotoxic amyloid β 1-42 oligomers from amyloid β 1-42 monomers. Also disclosed are methods of treating a patient suffering from diseases associated with the formation of soluble, globular, non-fibrillar, neurotoxic amyloid β 1-42 oligomers.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
15 January 2009 (15.01.2009)

PCT

(10) International Publication Number
WO 2009/008890 A1

(51) International Patent Classification:

A61K 31/381 (2006.01) A61P 25/28 (2006.01)

(21) International Application Number:

PCT/US2007/073408

(22) International Filing Date: 12 July 2007 (12.07.2007)

(25) Filing Language: English

(26) Publication Language: English

(71) Applicant (for all designated States except US): ACUMEN PHARMACEUTICALS, INC. [US/US]; 385 Oyster Point Blvd., Suite 9A, South San Francisco, California 94080 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): KRAFFT, Grant A. [US/US]; 1309 Evergreen Court, Glenview, Illinois 60025 (US). PRAY, Todd [US/US]; 35 9th Avenue, Unit 6, San Mateo, California 94554 (US). GOURE, William F. [US/US]; 657 Ridgcrest Circle, Livermore, California 94551 (US).

(74) Agents: TANNER, Lorna, L. et al.; FOLEY & LARDNER LLP, 975 Page Mill Road, Palo Alto, California 94304-1013 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report


(54) Title: METHODS OF MODIFYING AMYLOID β OLIGOMERS USING NON-PEPTIDIC COMPOUNDS

FIG.1

(57) Abstract: Disclosed are methods of inhibiting, regulating, and/or modulating the formation of soluble, globular, non-fibrillar, neurotoxic amyloid β 1-42 oligomers from amyloid β 1-42 monomers. Also disclosed are methods of treating a patient suffering from diseases associated with the formation of soluble, globular, non-fibrillar, neurotoxic amyloid β 1-42 oligomers.

 WO 2009/008890 A1

METHODS OF MODIFYING AMYLOID β OLIGOMERS USING NON-PEPTIDIC COMPOUNDS

BACKGROUND OF THE INVENTION

Field of the Invention

5 This invention relates to methods of inhibiting, regulating, and/or modulating the formation of soluble, globular, non-fibrillar, neurotoxic amyloid β_{1-42} oligomers from amyloid β_{1-42} monomers using non-peptidic compounds having a molecular weight of less than 1000. This invention also relates to methods of treating a patient suffering from diseases associated with the formation of soluble, globular, non-fibrillar, neurotoxic
10 amyloid β_{1-42} oligomers by administering non-peptidic compounds to the patients.

State of the Art


Alzheimer's disease (AD) is a fatal progressive dementia that has no cure at present. Although the molecular basis of the disease is not established, considerable evidence now implicates neurotoxins derived from amyloid beta ($A\beta$) peptides and in particular the 42-
15 amino acid amyloid beta peptide ($A\beta_{1-42}$). $A\beta$ is an amphipathic peptide, the abundance of which is increased by gene mutations and risk factors linked to AD. Fibrils formed from $A\beta$ constitute the cores of amyloid senile plaques, which are hallmarks of AD brain. Analogous fibrils generated *in vitro* are lethal to cultured brain neurons. These findings provided the central rationale for the original amyloid cascade hypothesis, a theory in which
20 memory loss was proposed to be the consequence of neuron death caused by fibrillar $A\beta$ (Hardy and Higgins (1992) Science 256:184-185).

Despite its strong experimental support and intuitive appeal, the original amyloid cascade hypothesis has proven inconsistent with key observations, including the poor correlation between dementia and amyloid senile plaque burden (Katzman (1988) Ann.
25 Neurol. **23**(2):138-144). Using a transgenic mouse model of AD, two surprising findings were obtained when the mice were treated with monoclonal antibodies against $A\beta$: (1) vaccinated mice showed reversal of memory loss, with recovery evident in 24 hours; and (2) cognitive benefits of vaccination accrued despite no change in senile plaque levels (Dodart et al. (2002) Nat. Neurosci **5**:452-457; Kotilinek et al. (2002) J. Neurosci. **22**:6331-6335).

Such findings are not consistent with a mechanism for memory loss dependent on neuron death caused by amyloid fibrils.

Salient flaws in the original amyloid cascade hypothesis have been eliminated by an updated amyloid cascade hypothesis that incorporates a role for additional neurologically active molecules formed by A β self-assembly. These molecules are amyloid β -derived diffusible ligands (ADDLs), which assemble from A β_{1-42} at low concentrations (Lambert et al. (1998) Proc. Natl. Acad. Sci. USA **95**:6448-6453). Essentially the missing links in the original amyloid cascade hypothesis, ADDLs rapidly inhibit long term potentiation (Lambert et al. (1998) Proc. Natl. Acad. Sci. USA **95**:6448-6453; Walsh et al. (2002) Nature **416**: 535-539; Wang et al. (2002) Brain Res. **924**:133-140), a classic experimental paradigm for memory and synaptic plasticity. In the updated A β cascade hypothesis memory loss stems from synapse failure, prior to neuron death, with failure being caused by ADDLs, not fibrils (Hardy and Selkoe (2002) Science **297**:353-356). ADDLs occur in brain tissue and are strikingly elevated in AD brain tissue compared to age matched controls (Kayed et al. (2002) Science **300**:486-489; Gong et al. (2003) Proc. Natl. Acad. Sci. USA **100**:10417-10422) and in AD transgenic mice models (Kotilinek et al. (2002) J. Neurosci. **22**:6331-6335; Chang et al. (2003) J. Mol. Neurosci. **20**:305-313).

A simplistic mechanistic approach to this theory can be illustrated as follows:



where formation of ADDLs is a separate pathway from formation of amyloid senile plaque both of which are in equilibrium with monomeric A β_{1-42} .

Further experiments have shown important neurological properties of ADDLs. ADDLs were shown to have selective toxicity to hippocampal CA1 neurons compared with CA3 neurons, and the complete absence of toxicity towards cerebellar neurons (Kim et al. (2003) FASEB J. **17**:118-120). Ventricular injection of A β_{1-42} oligomers into wild-type rats resulted in rapid, compromised behavioral models with complete recovery occurring within 24 hours (Cleary et al. (2005) Nat. Neurosci. **8**:79-84) and these deficits are attributed to higher order oligomers, specifically 12-mer oligomers (Lesne et al. (2006) Nature **440**:352-357). ADDL binding to neurons occurs with high specificity and is localized to post-

synaptic receptors on a subset of hippocampal neurons (Lacor et al. (2004) *J. Neurosci.* 24:10191-10200). This triggers the rapid and persistent up-regulation of the immediate early gene product arc, translation of which is activity dependent at polyribosomes localized to subsets of dendritic spines (Steward et al. (1998) *Neuron* 21:741-751; Guzowski et al. (2000) *J. Neurosci.* 20:3993-4001). More recently, ADDLs have been implicated as upstream activators of tau phosphorylation and have been shown to interfere with animal behavior at femtomolar levels (Matsubara et al. (2004) *Neurobiol. Aging* 25:833-841).

The reversibility of memory loss in mouse models, coupled with the neurological properties of ADDLs and their presence in an AD brain, provides strong support for the hypothesis that AD is a disease of ADDL-induced synaptic failure (Lambert et al. (1998) *Proc. Natl. Acad. Sci. USA* 95:6448-6453; Klein et al. (2001) *Trends Neurosci.* 24:219-220; Selkoe (2002) *Science* 298:789-791).

The use of antibodies specific to ADDLs is a powerful way to modulate the equilibrium between monomeric $A\beta_{1-42}$ and ADDLs thereby providing treatment for disease conditions mediated by ADDLs. However, antibody delivery is typically limited to injectable solutions which pose patient compliance issues as well as the presence of an attending clinician. Small molecules that modulate this equilibrium, deliverable by non-injectable means such as oral delivery, transdermal delivery, pulmonary delivery, nasal delivery, etc. would be particularly beneficial.

A number of small molecules developed originally as amyloid fibril blockers are purported to possess $A\beta$ oligomer assembly blocking properties. Some of these compounds include AlzhemdTM (Gervais (2004) *Neurobiol. Aging* 25:S11-12), Clioquinol (Ritchie et al. (2003) *Arch. Neurol.* 60:1685-1691), substituted β -cyclodextrins (Yu et al. (2002) *J. Mol. Neurosci.* 19:51-55), trehalose (Lui (2005) *Neurobiol. Disease* 20:74-81), simple amino, carbonyl, and nitro substituted phenols (De Felice et al. (2001) *FASEB J.* March 20; De Felice et al. (2004) *FASEB J.* 18:1366-1372), Curcumin (Yang et al. (2005) *J. Biol. Chem.* 280(7):5892-5901), cyclohexanehexol analogs (McLaurin et al. (2006) *Nature Med.* 12:801-808), spirosterols (Lecanu et al. (2004) *Steroids* 69:1-16) and tricyclic pyrones (Maeqawa et al. (2006) *J. Neurochem.* 98:57-67). Two of these compounds, AlzhemdTM and Clioquinol, have progressed into clinical trials.

AlzhemedTM (3-amino-1-propanesulfonic acid), a so-called "GAG mimetic," is proposed to reduce soluble and insoluble amyloid levels by binding to A β monomer, although no experimental details have appeared to confirm the proposed mode of action. AlzhemedTM has recently completed a 20 month open-label extension of a Phase II trial, and
5 there are reports of slowed cognitive decline in some patients with mild AD, however, no efficacy was observed during the blinded phase of the study (Gervais (2004) Neurobiol. Aging **25**:S11-12).

The second compound in a phase II clinical trial, Clioquinol, was shown to stabilize the patients' cognitive ability compared to untreated patients and showed lower A β_{1-42}
10 levels in their plasma (Ritchie et al. (2003) Arch. Neurol. **60**:1685-1691). However, a toxic impurity (a di-iodo form of Clioquinol) made during production has resulted in the study being halted and Clioquinol being replaced with an analog termed PBT2 (Blennow et al. (2006) Lancet **368**:387-403).

Lastly, an unidentified compound or compounds from an extract of ginkgo biloba
15 leaves was reported to lower the levels of A β_{1-42} trimers and tetramers and increase the levels of high molecular weight polymers in a dose dependent manner (Yao et al. (2001) Brain Res. **889**:181-190). Dose dependent protection against A β oligomer induced toxicity to PC-12 cells was also reported.

Of the compounds reported to block A β assembly or bind to A β_{1-42} monomer, few
20 appear to have high therapeutic potential. Given its very simple structure and hydrophilic properties, it is highly unlikely that AlzhemedTM has high and selective affinity for A β_{1-42} monomer. Any effect that AlzhemedTM has on A β aggregation or disaggregation is likely attributable to its interaction with ionic residues near the N-terminus of A β_{1-42} . The cyclodextrins do not have either lead-like or drug-like properties that would recommend
25 them for development (Oprea et al. (2001) J. Chem. Inf. Comput. Sci. **41**:1308-1315; Vieth et al. (2004) J. Med. Chem. **47**:224-232), and the phenols of De Felice contain aldehyde and nitro functionalities that are often considered reactive and excluded from screening libraries (Walters and Namchuk (2003) Nat. Rev. **2**:259-266). A number of molecules containing the phenol functionality have been reported as "frequent hitters" in screening libraries
30 (Roche et al. (2002) J. Med. Chem. **45**:137-142). Thus, further evaluation of the activity and selectivity of the phenols of De Felice is needed to confirm that these compounds are

valid hits. Some compounds with a steroidal backbone have been reported to be promiscuous inhibitors due to an unexpected self aggregation process (McGovern et al. (2002) J. Med. Chem. **45**:1712-1722), which may explain the ambiguous spirosterol results. Finally, the active ingredient in the ginkgo biloba extract is unknown. Thus, most of the purported A β assembly blockers would not be considered compounds for therapeutic development.

Notwithstanding these putative results and as noted above, binding assays indicate that these compounds are, at best, moderate antagonists to ADDL formation.

Accordingly, it would be particularly beneficial to provide for small molecules which provide enhanced inhibition, regulation, and/or modulation of ADDL formation.

SUMMARY OF THE INVENTION

This invention is directed to the discovery that soluble, globular, non-fibrillar, neurotoxic A β ₁₋₄₂ (ADDL) formation can be antagonized by substantially pure non-peptidic compounds having a molecular weight of less than 1500, preferably less than 1000, which compounds antagonize ADDL formation at levels higher than those previously achievable. This invention is further directed to the discovery of numerous scaffolds which exhibit this enhanced antagonism evidencing that it is not scaffold-dependent.

Accordingly, in one of its method aspects, this invention is directed to a method for antagonizing neurotoxic ADDL formation from monomeric A β ₁₋₄₂ by contacting monomeric A β ₁₋₄₂ with a substantially pure non-peptidic compound, said compound being characterized by:

- (a) having a molecular weight of less than 1000;
- (b) being an antagonist against formation of neurotoxic ADDLs from A β ₁₋₄₂ monomers; and
- (c) exhibiting an IC₅₀ of about 5 μ M or less in the assay of Example 1, which measures the formation of neurotoxic ADDLs.

In yet another embodiment, the invention is directed to a method of inhibiting, regulating and/or modulating the ADDL-induced neuronal dysfunction and/or neurotoxicity in a neuronal cell by inhibiting the formation of ADDLs. The method comprises contacting

$A\beta_{1-42}$ monomers which may be in the presence of neuronal cells with an effective amount of a substantially pure non-peptidic compound, said compound being characterized by:

- (a) having a molecular weight of less than 1000;
- (b) being an antagonist against formation of neurotoxic ADDLs from $A\beta_{1-42}$ monomers; and
- (c) exhibiting an IC_{50} of about 5 μ M or less in the assay of Example 1, which measures the formation of neurotoxic ADDLs.

In another embodiment, the invention is directed to a method for inhibiting oligomerization or further oligomerization of monomeric $A\beta_{1-42}$ into neurotoxic ADDLs which method comprises contacting monomeric $A\beta_{1-42}$ with an effective amount of a substantially pure non-peptidic compound, said compound being characterized by:

- (a) having a molecular weight of less than 1000;
- (b) being an antagonist against formation of neurotoxic ADDLs from $A\beta_{1-42}$ monomers; and
- (c) exhibiting an IC_{50} of about 5 μ M or less in the assay of Example 1, which measures the formation of neurotoxic ADDLs.

In another embodiment, the invention is directed to a method of inhibiting, regulating and/or modulating ADDL formation or the activity of such ligand in a patient suffering from or at risk from suffering from a disease associated with the formation of $A\beta_{1-42}$ oligomers. The method comprises administering to the patient a therapeutically effective amount of a substantially pure non-peptidic compound, said compound being characterized by:

- (a) having a molecular weight of less than 1000;
- (b) being an antagonist against formation of neurotoxic ADDLs from $A\beta_{1-42}$ monomers; and
- (c) exhibiting an IC_{50} of about 5 μ M or less in the assay of Example 1, which measures the formation of neurotoxic ADDLs.

In yet another embodiment, the invention is directed to a method for treating a patient suffering from or at risk of suffering from an ADDL-related disease selected from the group consisting of Alzheimer's disease, Down's Syndrome, stroke, mild cognitive impairment, focal ischemia associated dementia, and neuronal degeneration. The method

comprises administering to said patient a therapeutically effective amount of a substantially pure non-peptidic compound, said compound being characterized by:

- (a) having a molecular weight of less than 1000;
- (b) being an antagonist against formation of neurotoxic ADDLs from A β ₁₋₄₂ monomers; and
- (c) exhibiting an IC₅₀ of about 5 μ M or less in the assay of Example 1, which measures the formation of neurotoxic ADDLs.

In some embodiments of the invention, the compounds have a molecular weight of less than 1500. In other embodiments, the compounds are characterized in that they exhibit an inhibition in the formation of neurotoxic ADDLs as measured by an IC₅₀ of about 2 μ M or less in the assay of Example 1 and, more preferably, 1 μ M or less.

In another embodiment, the present invention relates to a composition for use in the treatment of a patient suffering from or at risk of suffering from a disease selected from the group consisting of Alzheimer's disease, Down's Syndrome, stroke, mild cognitive impairment, focal ischemia associated dementia, and neuronal degeneration wherein the composition comprises a therapeutically effective amount of a substantially pure non-peptidic compound, said compound being characterized by:

- (a) having a molecular weight of less than 1000;
- (b) being an antagonist against formation of neurotoxic ADDLs from A β ₁₋₄₂ monomers; and
- (c) exhibiting an IC₅₀ of about 5 μ M or less in the assay of Example 1, which measures the formation of neurotoxic ADDLs.

The present invention also relates to a method a manufacturing a medicament comprising the compound as set forth in the embodiments in this section.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 shows representative dose dependent assembly inhibition of compounds described herein using FRET analysis. The results of Test Compound A assayed at concentrations between 0.05 to 3 μ M are shown as well as the results of Test Compound B assayed at a concentration of 30 μ M. The positive and negative controls are also shown.

The X axes indicates time in minutes, where as the Y axes indicates the relative fluorescence units (RFU) X 10³ measured by the FRET assay in Example 1.

FIG. 2 shows representative dose dependent assembly inhibition of the putative amyloid fibril blocker compound AlzhemedTM (Neurochem) tested in the FRET assay
5 described herein. The positive and negative controls are also shown. The X axes indicates time in minutes, where as the Y axes indicates the relative fluorescence units (RFU) X 10³ measured by the FRET assay.

DETAILED DESCRIPTION OF THE INVENTION

A. Methods of the Invention

10 Before the methods are described, it is to be understood that the invention is not limited to the particular methodologies, protocols, cell lines, assays, and reagents described, as these may vary. It is also to be understood that the terminology used herein is intended to describe particular embodiments of the present invention, and is in no way intended to limit the scope of the present invention as set forth in the appended claims.

15 It must be noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural references unless the context clearly dictates otherwise.

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those
20 described herein can be used in the practice or testing of the present invention, the preferred methods, devices, and materials are now described. All publications cited herein are incorporated herein by reference in their entirety. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

25 The definitions used herein are limited to the application of small molecules as they relate to ADDL aggregation or oligomerization and diseases mediated by such.

This invention is directed to the discovery that the formation of soluble, oligomeric, globular, non-fibrillar, neurotoxic $A\beta_{1-42}$ peptides (ADDLs) can be antagonized by substantially pure non-peptidic compounds having a molecular weight of less than 1500, preferably less than 1000. The compounds antagonize ADDL formation at levels higher
5 than those previously achievable.

Without being limited by any theory, it is believed that the administration of an therapeutically effective amount of one or more of the compounds described herein will interact with key assembly motifs within the $A\beta_{1-42}$ monomers or within critical motifs on the $A\beta_{1-42}$ oligomers. This interaction, in turn, will prevent the formation of neurotoxic
10 ADDLs or the activity of such ligands. The disruption of the ADDLs or the activity of such ligands will protect long term potentiation of neuronal cells thereby obviating and/or reversing the neurotoxicity associated with ADDL. In addition, this interaction does not interfere with the formation of $A\beta$ senile plaques.

The term “non-peptidic compound” refers to a compound, examples of which are
15 described herein, which are not composed of peptides and/or proteins. It is understood that the presence of 1 to 10, or 1 to 5, or 1 to 2 amino acid residues attached to the compound scaffolds disclosed herein do not render such scaffolds peptidic provided that the molecular weight of the compound is less than 1500, preferably less than 1000, and the amino acid residues do not possess any antigen binding function and further provided that the scaffold
20 itself in the absence of the amino acid residues possesses inhibition of ADDL formation as set forth in Example 1 herein. In a preferred embodiment, the non-peptidic compounds described herein contain no amino acid residues derived from one of the 20 naturally occurring amino acids.

The term “peptides” and “proteins” refer to high molecular weight compounds
25 having a plurality of amino acid residues bound through amido (-C(O)-NR-) bonds. The amino acid residues are typically derived from one of the 20 naturally occurring amino acids.

The term “soluble” means the ability for a given substance, the solute (an example in the instant invention is the $A\beta_{1-42}$ oligomer) to dissolve in a solvent. Within the context of

the instant invention, soluble A β oligomers are capable of being fractionated by centrifugation.

The term “oligomeric” means a protein complex of a finite number of monomer subunits. In the context of the invention, oligomers are referred to as trimers, low-n-mers, dodecamers (12-mers), and large-n-multimers composed of A β ₁₋₄₂ peptides. The term
5 “oligomeric” does not include senile amyloid plaques.

The term “globular” means a large soluble protein complex, which is to be distinguished from fibrils and amyloid plaques. Preferably, the globular structure ranges in size from 4 nanometers (nm) to about 12 nm, preferably, from about 4.7 to about 11 nm,
10 which can be observed upon atomic force microscope analysis (AFM) of supernatant fractions of A β ₁₋₄₂ soluble oligomer preparations as described in US Patent No. 6,218,506.

The term “non-fibrillar” means the A β ₁₋₄₂ peptides and oligomeric complexes that are not aligned in a morphologically distinct pattern known as amyloid protofibrils or amyloid fibrils.

The term “ADDL” is conventionally defined as amyloid beta-derived diffusable
15 ligands which have the following characteristics: soluble, oligomeric, globular, non-fibrillar, neurotoxic A β ₁₋₄₂ peptides.

The term “substantially pure” is defined as substantially free of impurities, such as less than 20% impurities. In one embodiment, a compound is substantially pure if it
20 contains less than 10% impurities and, in another embodiment, if it contains less than 1% impurities.

The compounds described herein are useful in a method for inhibiting, regulating and/or modulating assembly of ADDLs either *in vitro* or *in vivo*.

The terms “disease,” “disorder,” and “condition” are used inclusively and refer to
25 any condition mediated at least in part by ADDLs. In the context of this invention the disease may be associated with insoluble amyloid fibrils, senile plaques, neurofibrillary tangles, and/or the over-expression of amyloid β ₁₋₄₂ protein. Examples include, but are not limited to, Alzheimer’s disease, Down’s Syndrome, mild cognitive impairment, stroke,

focal ischemia associated dementia, and neuronal degeneration. Patients amenable to treatment include individuals at risk of disease but not exhibiting symptoms, as well as patients presently exhibiting symptoms. Therefore, the compounds described herein can be administered prophylactically to the general population without the need for any assessment
5 of the risk of the patient.

The term “patient” refers to animals, including mammals, humans, and non-human mammals. In certain embodiments, a patient is an animal, particularly an animal selected from a mammalian species including rat, rabbit, bovine, ovine, porcine, canine, feline, murine, equine, and primate, particularly human.

10 The methods are especially useful for individuals who have a known genetic risk of Alzheimer’s disease. Such individuals include those having relatives who have been diagnosed with the disease and those whose risk is determined by analysis of genetic or biochemical markers. Genetic markers of risk for Alzheimer’s disease include mutations in the APP gene, particularly mutations at position 717 and positions 670 and 671 referred to
15 as the Hardy and Swedish mutations respectively. Other markers of risk are mutations in the presenilin genes, PS1 and PS2, and ApoE4, family history of Alzheimer’s Disease, hypercholesterolemia or atherosclerosis. Individuals presently suffering from Alzheimer’s disease can be recognized from characteristic dementia, as well as the presence of risk factors described above. In addition, a number of diagnostic test are available for
20 identifying individuals who have Alzheimer’s disease. These include measurement of CSF tau and $A\beta_{1-42}$ levels. Individuals suffering from Alzheimer’s disease can also be diagnosed by ADRDA criteria or the method disclosed herein.

In asymptomatic patients, treatment can begin at any age (e.g., 10, 20, 30 years of age). Usually, however, it is not necessary to begin treatment until a patient reaches 40, 50,
25 60, or 70 years of age. Treatment typically entails multiple dosages over a period of time. Treatment can be monitored by assaying for the presence of ADDLs over time.

“Treating” or “treatment” of a disease includes: (1) preventing the disease, i.e., causing the clinical symptoms of the disease not to develop in a patient that may be exposed to or predisposed to the disease but does not yet experience or display symptoms of the
30 disease; (2) inhibiting the disease, i.e., arresting or reducing the development of the disease

or its clinical symptoms; or (3) relieving the disease, i.e., causing regression of the disease or its clinical symptoms.

The term “suffering” as it related to the term “treatment” refers to a patient or individual who has been diagnosed with or is predisposed to a disease. A patient may also
5 be referred to being “at risk of suffering” from a disease. This patient has not yet developed characteristic disease pathology, however are know to be predispose to the disease due to family history, being genetically predispose to developing the disease, or diagnosed with a disease or disorder that predisposes them to developing the disease to be treated.

In addition to Alzheimer’s disease, several other disease are know to be associated
10 with $A\beta_{1-42}$ formation including, but are not limited to, Down’s Syndrome, stroke and mild cognitive impairment. It is conceivable that similar to Alzheimer’s disease, treatment of patients suffering from or at risk of suffering from these diseases is possible due to the parallel mechanisms of the diseases.

The term “senile plaque” or “senile plaque formation” refers to the extracellular
15 deposit of amyloid in the gray matter of the brain. The deposits are associated with degenerative neural structures. It is understood that senile plaque is different from and distinguished over ADDLs.

Similarly, over-expression of $A\beta_{1-42}$ is associated with focal ischemia associated dementia and neuronal degeneration. Over-expression of $A\beta_{1-42}$ is believed to result in
20 accumulation of ADDLs, thereby inducing neurotoxicity. Treating a patient suffering from or at risk of suffering from one of these diseases by administration of one or more of the compounds described herein will ameliorate the neurotoxicity of over-expressed $A\beta_{1-42}$.

The term “neurotoxicity” refers to the toxic effect of ADDLs on neuronal cells either
25 *in vitro* and/or *in vivo*. ADDLs bind to specific neuronal receptors triggering aberrant neuronal signaling, which compromises long term potentiation and causes memory deficits. Thus, ADDLs alter the function of the neuronal cell in such a manner that, while still viable, the neuron does not properly function. Such altered functionality is referred to herein as “neuronal dysfunction,” which is a subclass of neurotoxicity. Persistent ADDL signaling causes aberrant transcription and the progressive loss of synapses, and very long term

persistent ADDL signaling and accumulated structural pathology leads to eventual neuron death and gross brain dystrophy.

In therapeutic applications, a pharmaceutical composition containing one or more compounds described herein is administered to a patient suspected of, or already suffering
5 from such a disease associated with the accumulation of ADDLs, wherein said compounds are administered in an amount sufficient to cure, or at least partially arrest, the symptoms of the disease (biochemical, histological and/or behavioral), including its complication and intermediate pathological phenotypes in development of the disease. In prophylactic applications, a pharmaceutical composition containing one or more compounds described
10 herein is administered to a patient susceptible to, or otherwise at risk of, a disease associated with the accumulation of ADDLs, wherein said compounds are administered in an amount sufficient to eliminate or reduce the risk, lessen the severity, or delay the outset of the disease. This includes biochemical, histological and/or behavioral symptoms of the disease, its complications and intermediate pathological phenotypes presenting during development
15 of the disease.

In some methods, administration of the compound reduces or eliminates mild cognitive impairment in patients that have not yet developed characteristic Alzheimer's pathology. In particular embodiments, a therapeutically effective amount intends to indicate the amount of one or more compounds described herein administered or delivered to the
20 patient which is most likely to result in the desired response to treatment. A further description of the embodiments relating to enhanced cognitive function may be found in PCT application no. PCT/US2007/_____, filed on July 12, 2007, titled "Methods of Enhancing Cognitive Function Using Non-Peptidic Compounds," Attorney Docket No. 089265-1450, which is hereby incorporated by reference in its entirety.

25 An "effective amount" is an amount of one or more of the compounds described herein which treats the ADDL mediated disease. Preferably, the compounds of this invention will decrease ADDL formation either *in vitro* or *in vivo* by at least 10%, 25%, 40%, 60%, 80%, 90% or 95% as compared to control.

The "therapeutically effective amount" will vary depending on the compound, the
30 disease and its severity and the age, weight, etc., of the patient to be treated all of which is

within the skill of the attending clinician. It is contemplated that a therapeutically effective amount of one or more of the compounds described herein will alter ADDL formation (including inhibiting or reversing formation of ADDLs) in the patient as compared to binding of ADDLs in the absence of treatment. As such, impairment of long term
5 potentiation and subsequent memory formation is decreased. A therapeutically effective amount is distinguishable from an amount having a biological effect (a “biologically effective amount”). A compound of the present invention may have one or more biological effects *in vitro* or even *in vivo*, such as reduction in ADDL formation to some extent. A biological effect, however, may not result in any clinically measurable therapeutically effect
10 as described above as determined by methods within the skill of the attending clinician.

A “neuronal cell” or “neuron” is a cell that transmits and processes signals in the brain or other parts of the nervous system. Additionally, a neuronal cell, as used in the invention, can be isolated from animal brain tissue and grown in tissue culture. The isolated cells can be comprised of an established neuronal cell line selected from for example, but
15 are not limited to, MC65; HCN-2; SH-SY5Y; SK-N-AS; SK-N-FI; SK-N-DZ; H19-7/IGF-IR; QNR/D; QNR/K2; C8-D30; C8-S; C8-D1A; OLGA-PH-J/92; Daoy; RSC96; SW10; RT4-D6P2T; RN33B; PC-12; DBRTG-05MG; C8-B4; SK-N-SH; B35; R3[33-10ras3]; Neuro-2A; and HCN-1A or any genetic, chemical, and/or biochemical modified variants thereof. The isolated cells can also be comprised of primary cells and/or astrocytes isolated
20 from neuronal tissues selected from, for example, but are not limited to, the hippocampus; cerebellum; cortex; hypothalamus; mid-brain; spinal cord; striatum; frontal lobe; temporal lobe; parietal lobe; occipital lobe and any genetic, chemical, and/or biochemical modified variants thereof. The isolated, cultured animal cell can be comprised of a neural stem cell or any differentiated, genetic, chemical, and/or biochemical modified variants thereof.

25 As used herein, the term “neuronal tissue” refers to any portion of the central nervous system including, but not limited to, the brain or spinal cord. Neuronal tissue can be composed of, at least in part, neuronal cells.

The term “amyloid fibrils” means protein aggregates sharing specific structural traits. Histopathological techniques generally identify the structures by apple-green
30 birefringence when stained with Congo red and seen under polarized light.

The term “tangles” means the neurofibrillary tangles formed inside of degenerating neurons by bundling of paired helical filaments, which assemble from hyperphosphorylated forms of the microtubule-associated protein known as tau.

B. Compounds

5 The compounds useful in the methods described herein are substantially pure, non-peptidic and have a molecular weight of less than 1000. In one embodiment, the compounds useful in the methods of the invention preferably contain one or more and any combination of the following characteristics: (1) low or sub-micromolar potency when tested in the FRET assay described herein; (2) non-aggregating; (3) little or no neuronal
10 toxicity when administered to a patient; (4) favorable solubility in an aqueous environment; (5) chemically tractable; (6) dose dependent characteristics; (7) reversibly bind to the A β protein; (8) capable of amyloid β monomer binding; (9) capable of binding soluble amyloid β oligomers.

In one embodiment of the invention, the compounds useful for treating patients are
15 suitable for oral delivery. In this embodiment, the compounds are compliant with Lipinski's rule-of-five which provides a criteria to evaluate drug likeness. The rule states that, in general, an orally active drug has: no more than 5 hydrogen bond donors (OH and NH groups); no more than 10 hydrogen bond acceptors (notably N and O); a molecular weight under 500 g/mol; and a partition coefficient log P less than 5.

20 1. Compound Selection

A preferred method of selecting compounds for their use in the methods of the invention involves assaying the compounds with Fluorescence Resonance Energy Transfer (FRET). FRET has been used to measure, detect, identify, assay, analyze, and characterize various interactions and processes in biological systems (*see e.g.*, Mitra et al. (1996) *Gene*
25 **173**:13-17; De Angelis (1999) *Physiol. Genomics*. **21**:93-99; Latif and Graves (2000) *Thyroid* **10**(5):407-412; Rye (2001) *Methods* **24**(3):278-288; Kenworthy (2001) *Methods* **24**(3):289-296; Periasamy (2001) *J. Biomed. Opt.* **6**(3):287-291; Truong and Ikura (2001) *Curr. Opin. Struct. Biol.* **11**(5):573-578; Zhang et al. (2002) *Nat. Rev. Mol. Cell. Biol.* **3**(12):906-918; Sitte and Freissmuth (2003) *Eur. J. Pharmacol.* **479**:229-236; Milligan
30 (2004) *Eur. J. Pharm. Sci.* **21**(4):397-405; Herman et al. (2004) *Methods Mol. Biol.*

261:351-370; Roda et al. (2004) Trends Biotechnol. **22**(6):295-303; Wallrabe and Periasamy (2005) Curr. Opin. Biotechnol. **16**(1):19-27; Milligan and Bouvier (2005) FEBS J. **272**(12):2914-2915; references in any of the foregoing; and the like).

FRET methods, protocols, techniques, assays, and the like are described generally and specifically in a number of patents and patent applications, including: U.S. Patent No. 6,908,769; U.S. Patent No. 6,824,990; U.S. Patent No. 6,762,280; U.S. Patent No. 6,689,574; U.S. Patent No. 6,661,909; U.S. Patent No. 6,642,001; U.S. Patent No. 6,639,078; U.S. Patent No. 6,472,156; U.S. Patent No. 6,456,734; U.S. Patent No. 6,376,257; U.S. Patent No. 6,348,322; U.S. Patent No. 6,323,039; U.S. Patent No. 6,291,201; U.S. Patent No. 6,280,981; U.S. Patent No. 5,914,245; U.S. Patent No. 5,661,035; references in any of the foregoing; and the like.

Similarly, fluorescence polarization (FP) has also been used to measure, detect, identify, assay, analyze, and characterize various interactions and processes in biological systems (*see e.g.*, Lundblad et al. (1996) Mol. Endocrinol. **10**(6):607-612; Nasir and Jolley (1999) Comb. Chem. High Throughput Screen. **2**(4):177-190; Park and Raines (2004) Methods Mol. Biol. **261**:161-166; references in any of the foregoing; and the like).

Fluorescence polarization (FP) methods, protocols, techniques, assays, and the like are described generally and specifically in a number of patents and patent applications, including: U.S. Patent No. 6,794,158; U.S. Patent No. 6,632,613; U.S. Patent No. 6,630,295; 6,596,546; U.S. Patent No. 6,569,628; 6,555,326; U.S. Patent No. 6,511,815; U.S. Patent No. 6,448,018; U.S. Patent No. 6,432,632; U.S. Patent No. 6,331,392; U.S. Patent No. 6,326,142; U.S. Patent No. 6,284,544; U.S. Patent No. 6,207,397; U.S. Patent No. 6,171,807; U.S. Patent No. 6,066,505; U.S. Patent No. 5,976,820; U.S. Patent No. 5,804,395; U.S. Patent No. 5,756,292; U.S. Patent No. 5,445,935; U.S. Patent No. 5,427,960; U.S. Patent No. 5,407,834; U.S. Patent No. 5,391,740; U.S. Patent No. 5,315,015; U.S. Patent No. 5,206,179; U.S. Patent No. 5,070,025; U.S. Patent No. 5,066,426; U.S. Patent No. 4,952,691; U.S. Patent No. 4,863,876; U.S. Patent No. 4,751,190; U.S. Patent No. 4,681,859; U.S. Patent No. 4,668,640; U.S. Patent No. 4,614,823; U.S. Patent No. 4,585,862; U.S. Patent No. 4,510,251; U.S. Patent No. 4,476,229; U.S. Patent No. 4,429,230; U.S. Patent No. 4,420,568; U.S. Patent No. 4,203,670; references in any of the foregoing; and the like.

FRET and FP have been used in the field of amyloid research (*see e.g.*, U.S. Patent No. 6,927,401; U.S. Patent No. 6,906,104; U.S. Patent No. 6,905,827; U.S. Patent No. 6,881,546; U.S. Patent No. 6,864,290; U.S. Patent No. 6,864,103; U.S. Patent No. 6,858,383; U.S. Patent No. 6,846,813; U.S. Patent No. 6,828,106; U.S. Patent No. U.S. Patent No. 6,803,188; U.S. Patent No. 6,770,448; U.S. Patent No. 6,713,276; U.S. Patent No. 6,600,017; U.S. Patent No. 6,515,113; U.S. Patent No. 6,495,664; U.S. Patent No. 6,323,039; U.S. Patent No. 6,294,330; U.S. Patent No. 6,280,981; U.S. Patent No. 6,197,928; U.S. Patent No. 5,981,200; Kim and Lee (2004) *Biochem. Biophys. Res. Commun.* **316**(2):393-397; Bacskai et al. (2003) *J. Biomed. Opt.* **8**(3):368-375; Gorman, P.M. et al. (2003) *J. Mol. Biol.* **325**(4):743-757; Garzon-Rodrequez et al. (1997) *J. Biol. Chem.* **272**(34):21037-21044; Lindgren et al. (2005) *Biophys. J.* **88**(6):4200-4212; Lewis et al. (2004) *Neurobiol. Aging* **25**(9):1175-1185; Leissring et al. (2003) *J. Biol. Chem.* **278**(39):37314-37320; Taylor et al. (2003) *J. Protein Chem.* **22**(1):31-40; Allsop et al. (2001) *Biochem. Soc. Symp.* **67**:1-14; Allsop et al. (2001) *Biochem. Biophys. Res. Commun.* **285**(1):58-63; Huang et al. (2000) *J. Biol. Chem.* **275**(46):36436-36440; references in any of the foregoing; and the like).

2. Applications of FRET for Compound Discovery

The FRET assay of Example 1 was used on a variety of commercially available compound libraries to assess the specific inhibition formation of soluble amyloid β_{1-42} oligomers of each compound. Lead compounds were identified and further compound libraries were obtained. In addition, structure activity relationships around lead compounds were conducted leading to still further enhancements in activity.







3. Exemplary Compounds Useful in the Methods of the Invention

Certain examples of compounds useful in this invention are presented below in Table 1 below. It is to be understood that the illustration of these compounds is in no way limiting the invention to the compounds described in these tables and it is therefore contemplated that other compounds are suitable for use in this invention.

Also provided in the table are the compounds IC_{50} values as tested using the assay described in Example 1. In each case, the compounds recited either were commercially available from the source indicated in the table. It should also be noted that the following

compounds may exhibit stereoisomerism (i.e., *E* and *Z* isomers) and the invention contemplates use of either isomer and mixtures thereof.

Table 1. Exemplary Compounds

No.	Compound Structure	Compound Name	IC ₅₀ (μ M)	Source
1.		N-(2-Methoxy-phenyl)-2-oxo-2-{N'-[3-oxo-3-thiophen-2-yl-1-trifluoromethyl-prop-(<i>Z</i>)-ylidene]-hydrazino}-acetamide	3.9	deCODE
2.		2-[[1-(2-Hydroxy-3-methoxy-phenyl)-meth-(<i>E</i>)-ylidene-hydrazinoxyalyl]-amino]-6-methyl-4,5,6,7-tetrahydro-benzo[<i>b</i>]thiophene-3-carboxylic acid ethyl ester	3.5	Aldrich
3.		2-[[1-(2-Hydroxynaphthalen-1-yl)-meth-(<i>E</i>)-ylidene-hydrazinoxyalyl]-amino]-6-methyl-4,5,6,7-tetrahydro-benzo[<i>b</i>]thiophene-3-carboxylic acid ethyl ester	4.4	Aldrich
4.		2-[[1-(2-Hydroxyphenyl)-meth-(<i>E</i>)-ylidene-hydrazinoxyalyl]-amino]-6-methyl-4,5,6,7-tetrahydro-benzo[<i>b</i>]thiophene-3-carboxylic acid ethyl ester	1.1	Aldrich
5.		2-(5-hydroxy-3-isobutyl-5-(trifluoromethyl)-4,5-dihydro-1H-pyrazol-1-yl)-N-(2-methoxyphenyl)-2-oxoacetamide	3.2	ChemDiv
6.		(E)-2-hydroxy-N'-((1-hydroxynaphthalen-2-yl)methylene)benzohydrazide	3.8	deCODE

C. Testing and Administration

Effective doses of the compositions of the present invention, for the treatment of the above described diseases, vary depending upon many different factors, including means of administration, physiological state of the patient, whether the patient is human or an animal, other medications administered, and whether treatment is prophylactic or therapeutic. Usually, the patient is a human, but in certain embodiments, a patient is an animal, particularly an animal selected from a mammalian species including rat, rabbit, bovine, ovine, porcine, canine, feline, murine, equine, and primate.

The compounds can be administered on multiple occasions, wherein intervals between single dosages can be daily, weekly, monthly, or yearly. Intervals can also be irregular as indicated by measuring blood levels of $A\beta_{1-42}$ protein or ADDLs, or ADDL complexes in the patient. Alternatively, one or more of the compounds of the invention can be administered as a sustained-release formulation, in which case less frequent administration is required. Dosage and frequency may vary depending on the half-life of the compounds of the invention. In therapeutic applications, a relatively high dosage at relatively short intervals is sometimes required until progression of the disease is reduced or terminated, and preferably until the patient shows partial or complete amelioration of symptoms of the disease. Thereafter, the patient can be administered a prophylactic regime.

Administration of a pharmaceutical composition of the compounds described herein can be carried out via a variety of routes including, but are not limited to, oral, topical, pulmonary, rectal, subcutaneous, intradermal, intranasal, intracranial, intramuscular, intraocular, or intra-articular injection and the like. The most typical route of administration is oral, although other routes can be equally effective.

One or more compounds described herein can optionally be administered in combination with other biological or chemical agents that are at least partly effective in treatment of a $A\beta_{1-42}$ associated disease. An example of such an agent is, but are not limited to, $A\beta_{1-42}$ targeted antibodies as described in International Application Nos.: WO 2003/253673; WO 2006/014478, US Patent No. 2,489,195, US Publication No. 2007-0048312, and US Application No. 11/571,532, which are incorporated herein by reference.

The compounds described herein may be administered to a patient in an amount sufficient to inhibit, regulate and/or modulate the formation of neurotoxic ADDLs or the activity of such ligands in said patient. A skilled clinician would be able to readily ascertain appropriate amounts of the compounds described here to effectively inhibit, regulate and/or modulate the formation of neurotoxic ADDLs or the activity of such ligands in said patient. Contemplated amounts of the compounds described herein include for example, but are not limited to, from about 0.05 to 2000 mg/m²/day of one compound or more than one compound.

As noted above, the compounds described herein may be administered for example, but are not limited to, orally, topically, pulmonaryly, rectally, subcutaneously, intradermally, intranasally, intracranially, intramuscularly, intraocularly, or intra-arterially and the like. The carrier or excipient or excipient mixture can be a solvent or a dispersive medium containing for example, but are not limited to, various polar or non-polar solvents, suitable mixtures thereof, or oils. As used herein "carrier" or "excipient" means a pharmaceutically acceptable carrier or excipient and includes any and all solvents, dispersive agents or media, coating(s), antimicrobial agents, iso/hypo/hypertonic agents, absorption-modifying agents, and the like. The use of such substances and the agents for pharmaceutically active substances is well known in the art. Moreover, other or supplementary active ingredients can also be incorporated into the final composition.

Diseases which are treated by the methods described herein include Alzheimer's disease, Down's syndrome, stroke, mild cognitive impairment, focal ischemia associated dementia and neuronal degeneration.

D. Pharmaceutical Formulations and Routes of Administration

When employed as pharmaceuticals, the compounds of this invention are usually administered in the form of pharmaceutical compositions. These compounds can be administered by a variety of routes including oral, topical, pulmonary, rectal, subcutaneous, intradermal, intranasal, intracranial, intramuscular, intraocular, or intra-articular injection. These compounds are effective as both injectable and oral compositions. Such compositions are prepared in a manner well known in the pharmaceutical art and comprise at least one active compound.

This invention also includes pharmaceutical compositions which contain, as the active ingredient, one or more of the compounds described herein associated with pharmaceutically acceptable carriers. In making the compositions of this invention, the active ingredient is usually mixed with an excipient, diluted by an excipient or enclosed
5 within such a carrier which can be in the form of a capsule, sachet, paper or other container. The excipient employed is typically an excipient suitable for administration to patient. When the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions,
10 emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders.

In preparing a formulation, it may be necessary to mill the active compound to provide the appropriate particle size prior to combining with the other ingredients. If the
15 active compound is substantially insoluble, it ordinarily is milled to a particle size of less than 200 mesh. If the active compound is substantially water soluble, the particle size is normally adjusted by milling to provide a substantially uniform distribution in the formulation, *e.g.* about 40 mesh.

Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol,
20 mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, and methyl cellulose. The formulations can additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxy-benzoates; sweetening agents; and
25 flavoring agents. The compositions of the invention can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient by employing procedures known in the art.

Administration of therapeutic agents by intravenous formulation is well known in the pharmaceutical industry. An intravenous formulation should possess certain qualities
30 aside from being just a composition in which the therapeutic agent is soluble. For example, the formulation should promote the overall stability of the active ingredient(s), also, the

manufacture of the formulation should be cost effective. All of these factors ultimately determine the overall success and usefulness of an intravenous formulation.

Other accessory additives that may be included in pharmaceutical formulations of compounds of the present invention as follow: solvents: ethanol, glycerol, propylene glycol; 5 stabilizers: ethylene diamine tetraacetic acid (EDTA), citric acid; antimicrobial preservatives: benzyl alcohol, methyl paraben, propyl paraben; buffering agents: citric acid/sodium citrate, potassium hydrogen tartrate, sodium hydrogen tartrate, acetic acid/sodium acetate, maleic acid/sodium maleate, sodium hydrogen phthalate, phosphoric acid/potassium dihydrogen phosphate, phosphoric acid/disodium hydrogen phosphate; and 10 tonicity modifiers: sodium chloride, mannitol, dextrose.

The presence of a buffer may be necessary to maintain the aqueous pH in the range of from about 4 to about 8 and more preferably in a range of from about 4 to about 6. The buffer system is generally a mixture of a weak acid and a soluble salt thereof, *e.g.*, sodium citrate/citric acid; or the monocation or dication salt of a dibasic acid, *e.g.*, potassium 15 hydrogen tartrate; sodium hydrogen tartrate, phosphoric acid/potassium dihydrogen phosphate, and phosphoric acid/disodium hydrogen phosphate.

The amount of buffer system used is dependent on (1) the desired pH; and (2) the amount of drug. Generally, the amount of buffer used is in a 0.5:1 to 50:1 mole ratio of buffer:drug (where the moles of buffer are taken as the combined moles of the buffer 20 ingredients, *e.g.*, sodium citrate and citric acid) of formulation to maintain a pH in the range of 4 to 8 and generally, a 1:1 to 10:1 mole ratio of buffer (combined) to drug present is used.

One useful buffer in the invention is sodium citrate/citric acid in the range of 5 to 50 mg per mL of sodium citrate to 1 to 15 mg per mL of citric acid, sufficient to maintain an aqueous pH of 4-6 of the composition.

25 The buffer agent may also be present to prevent the precipitation of the drug through soluble metal complex formation with dissolved metal ions, *e.g.*, Ca, Mg, Fe, Al, Ba, which may leach out of glass containers or rubber stoppers or be present in ordinary tap water. The agent may act as a competitive complexing agent with the drug and produce a soluble metal complex leading to the presence of undesirable particulates.

In addition, the presence of an agent, *e.g.*, sodium chloride in an amount of about of 1-8 mg/mL, to adjust the tonicity to the same value of human blood may be required to avoid the swelling or shrinkage of erythrocytes upon administration of the intravenous formulation leading to undesirable side effects such as nausea or diarrhea and possibly to associated blood disorders. In general, the tonicity of the formulation matches that of human blood which is in the range of 282 to 288 mOsm/kg, and in general is 285 mOsm/kg, which is equivalent to the osmotic pressure corresponding to a 0.9% solution of sodium chloride.

The intravenous formulation can be administered by direct intravenous injection, *i.v.* bolus, or can be administered by infusion by addition to an appropriate infusion solution such as 0.9% sodium chloride injection or other compatible infusion solution.

The compositions can be formulated in an oral unit dosage form. The term "unit dosage forms" refers to physically discrete units suitable as unitary dosages for a patient, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.

The active compound is effective over a wide dosage range and is generally administered in a pharmaceutically effective amount. It, will be understood, however, that the amount of the compound actually administered will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.

For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid preformulation is then subdivided into unit dosage forms of the type described above containing from, for example, 0.05 to about 2000 mg of the active ingredient of the present invention.

The tablets or pills of the present invention may be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.

The liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include aqueous solutions suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil, or peanut oil, as well as elixirs and similar pharmaceutical vehicles.

Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described *supra*. Preferably the compositions are administered by the oral or nasal respiratory route for local or systemic effect. Compositions in preferably pharmaceutically acceptable solvents may be nebulized by use of inert gases. Nebulized solutions may be breathed directly from the nebulizing device or the nebulizing device may be attached to a face masks tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions may be administered, preferably orally or nasally, from devices which deliver the formulation in an appropriate manner.

The following formulation examples illustrate the contemplated pharmaceutical compositions of the present invention.

Formulation Example 1

Hard gelatin capsules containing the following ingredients are prepared:

Ingredient	Quantity (mg/capsule)
Active Ingredient	30.0
Starch	305.0
Magnesium stearate	5.0

The above ingredients are mixed and filled into hard gelatin capsules in 340 mg quantities.

Formulation Example 2

5 A tablet formula is prepared using the ingredients below:

Ingredient	Quantity (mg/tablet)
Active Ingredient	25.0
Cellulose, microcrystalline	200.0
Colloidal silicon dioxide	10.0
Stearic acid	5.0

The components are blended and compressed to form tablets, each weighing 240 mg.

Formulation Example 3

10 A dry powder inhaler formulation is prepared containing the following components:

Ingredient	Weight %
Active Ingredient	5
Lactose	95

The active ingredient is mixed with the lactose and the mixture is added to a dry powder inhaling appliance.

Formulation Example 4

15 Tablets, each containing 30 mg of active ingredient, are prepared as follows:

Ingredient	Quantity (mg/tablet)
Active Ingredient	30.0 mg
Starch	45.0 mg
Microcrystalline cellulose	35.0 mg
Polyvinylpyrrolidone (as 10% solution in sterile water)	4.0 mg
Sodium carboxymethyl starch	4.5 mg
Magnesium stearate	0.5 mg
Talc	1.0 mg

The active ingredient, starch, and cellulose are passed through a No. 20 mesh U.S. sieve and mixed thoroughly. The solution of polyvinylpyrrolidone is mixed with the resultant powders, which are then passed through a 16 mesh U.S. sieve. The granules so produced are dried at 50°C to 60°C and passed through a 16 mesh U.S. sieve. The sodium carboxymethyl starch, magnesium stearate, and talc, previously passed through a No. 30 mesh U.S. sieve, are then added to the granules which, after mixing, are compressed on a tablet machine to yield tablets each weighing 120 mg.

Formulation Example 5

10 Capsules, each containing 40 mg of medicament are made as follows:

Ingredient	Quantity (mg/capsule)
Active Ingredient	40.0 mg
Starch	109.0 mg
Magnesium stearate	1.0 mg
Total	150.0 mg

The active ingredient, starch and magnesium stearate are blended, passed through a No. 20 mesh U.S. sieve, and filled into hard gelatin capsules in 150 mg quantities.

Formulation Example 6

15 Suppositories, each containing 25 mg of active ingredient are made as follows:

Ingredient	Amount
Active Ingredient	25 mg
Saturated fatty acid glycerides to	2,000 mg

The active ingredient is passed through a No. 60 mesh U.S. sieve and suspended in the saturated fatty acid glycerides previously melted using the minimum heat necessary. The mixture is then poured into a suppository mold of nominal 2.0 g capacity and allowed
5 to cool.

Formulation Example 7

Suspensions, each containing 50 mg of medicament per 5.0 ml dose are made as follows:

Ingredient	Amount
Active Ingredient	50.0 mg
Xanthan gum	4.0 mg
Sodium carboxymethyl cellulose (11%)	
Microcrystalline cellulose (89%)	50.0 mg
Sucrose	1.75 g
Sodium benzoate	10.0 mg
Flavor and Color	q.s.
Purified water to	5.0 mL

10 The active ingredient, sucrose and xanthan gum are blended, passed through a No. 10 mesh U.S. sieve, and then mixed with a previously made solution of the microcrystalline cellulose and sodium carboxymethyl cellulose in water. The sodium benzoate, flavor, and color are diluted with some of the water and added with stirring. Sufficient water is then added to produce the required volume.

15

Formulation Example 8

Ingredient	Quantity (mg/capsule)
-------------------	----------------------------------

Active Ingredient	15.0 mg
Starch	407.0 mg
Magnesium stearate	3.0 mg
Total	425.0 mg

The active ingredient, starch, and magnesium stearate are blended, passed through a No. 20 mesh U.S. sieve, and filled into hard gelatin capsules in 425.0 mg quantities.

Formulation Example 9

5 A subcutaneous formulation may be prepared as follows:

Ingredient	Quantity
Active Ingredient	5.0 mg
Corn Oil	1.0 mL

Formulation Example 10

An intravenous formulation may be prepared as follows:

Ingredient	Quantity
Active Ingredient	250 mg
Isotonic saline	1000 mL

10 Another formulation employed in the methods of the present invention employs transdermal delivery devices (“patches”). Such transdermal patches may be used to provide continuous or discontinuous infusion of the compounds of the present invention in controlled amounts. The construction and use of transdermal patches for the delivery of pharmaceutical agents is well known in the art. See, *e.g.*, U.S. Patent 5,023,252, issued
15 June 11, 1991, herein incorporated by reference. Such patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents.

Frequently, it will be desirable or necessary to introduce the pharmaceutical composition to the brain, either directly or indirectly. Direct techniques usually involve

placement of a drug delivery catheter into the host's ventricular system to bypass the blood-brain barrier. One such implantable delivery system used for the transport of biological factors to specific anatomical regions of the body is described in U.S. Patent 5,011,472, which is herein incorporated by reference.

5 Indirect techniques, usually involve formulating the compositions to provide for drug latention by the conversion of hydrophilic drugs into lipid-soluble drugs. Latention is generally achieved through blocking of the hydroxyl, carbonyl, sulfate, and primary amine groups present on the drug to render the drug more lipid soluble and amenable to transportation across the blood-brain barrier. Alternatively, the delivery of
10 hydrophilic drugs may be enhanced by intra-arterial infusion of hypertonic solutions, which can transiently open the blood-brain barrier.

Other suitable formulations for use in the present invention can be found in Remington's Pharmaceutical Sciences, Mace Publishing Company, Philadelphia, PA, 17th ed. (1985).

15 As noted above, the compounds described herein are suitable for use in a variety of drug delivery systems described above. Additionally, in order to enhance the *in vivo* serum half-life of the administered compound, the compounds may be encapsulated, introduced into the lumen of liposomes, prepared as a colloid, or other conventional techniques may be employed which provide an extended serum half-life of the compounds. A variety of
20 methods are available for preparing liposomes, as described in, *e.g.*, Szoka, et al., U.S. Patent Nos. 4,235,871, 4,501,728 and 4,837,028 each of which is incorporated herein by reference.

In prophylactic applications, compositions are administered to a patient at risk of developing AD (determined for example by genetic screening or familial trait) in an amount
25 sufficient to inhibit the onset of symptoms of the disease. An amount adequate to accomplish this is defined as "prophylactically effective dose." Amounts effective for this use will depend on the judgment of the attending clinician depending upon factors such as the age, weight and general condition of the patient, and the like.

As noted above, the compounds administered to a patient are in the form of
30 pharmaceutical compositions described above. These compositions may be sterilized by

conventional sterilization techniques, or may be sterile filtered. The resulting aqueous solutions may be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration. The pH of the compound preparations typically will be between 3 and 11, more preferably from 5 to 9 and most preferably from 7 and 8. It will be understood that use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of pharmaceutical salts.

The following examples are offered to illustrate this invention and are not to be construed in any way as limiting the scope of this invention. Unless otherwise stated, all temperatures are in degrees Celsius.

10

EXAMPLES

The invention is further understood by reference to the following examples, which are intended to be purely exemplary of the invention. The present invention is not limited in scope by the exemplified embodiments, which are intended as illustrations of single aspects of the invention only. Any methods that are functionally equivalent are within the scope of the invention. Various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and accompanying figures. Such modifications fall within the scope of the appended claims.

In these examples and elsewhere, abbreviations have the following meanings:

μL or μl	=	Microliter
DMSO	=	dimethylsulfoxide
g	=	Gram
h	=	Hour
Hz	=	Hertz
M	=	Molar
mg	=	Milligram
min	=	Minute
mL	=	Milliliter
mM	=	Millimolar
mm	=	Millimeter
mmol	=	Millimolar
mol	=	Moles
MS	=	Mass Spectroscopy
N	=	Normal
nm	=	Nanometer
μM	=	Micromolar

Example 1

FRET Assay

Fluorescence (or Förster) Resonance Energy Transfer (FRET) is a distance-dependent, non-radiative transfer of energy in which the de-excitation of one fluorophore (donor) is coupled to excitation of another fluorophore (acceptor). FRET occurs if (1) the quantum of energy emitted by a donor fluorophore corresponds to an acceptor fluorophore's excitation energy, (2) the orientations of donor and acceptor transition dipoles are nearly parallel and (3) the donor fluorescent emission spectrum overlaps the acceptor absorption spectrum.

In this assay, assembly of $A\beta_{1-42}$ oligomer formation is monitored by FRET using N-terminal conjugates of fluorescein- $A\beta_{1-42}$ as both the donor and acceptor fluorophore (fluorescein-fluorescein $R_0 \sim 45 \text{ \AA}$). $A\beta_{1-42}$ monomers assembling into oligomeric species results in a decrease of fluorescence as the fluorescein labeled $A\beta_{1-42}$ peptides become proximal to each other and FRET efficiency increases. Inhibition of $A\beta_{1-42}$ assembly is observed as the absence or attenuation of fluorescein quenching.

FRET and FP assays are performed in 384-well Corning Non-Binding Surface, black, opaque microtiter plates, and the assay buffer consists of 50 mM MOPS-Tris (pH 8.0) with 100 mM $MgCl_2$. The assay volume, containing 0.2 μM FITC- $A\beta(1-42)$ and 0.8 μM $A\beta(1-42)$, is 50 μl and the temperature is 37°C. ADDL assembly is monitored on a Tecan GENios Pro plate reader, exciting at a wavelength of 485 nm and detecting emission at a wavelength of 515 nm. Kinetic traces are collected by recording fluorescence intensity and polarization readings every five minutes over about a three to about a six-hour time course. Negative control reactions, which do not appreciably assemble into ADDLs during this time, lack $MgCl_2$ but contain all other buffer and peptide components. Positive control reactions contain all buffer components in the absence of added small molecule or antibody reagents. To test for ADDL assembly inhibition, the non-peptidic compound was incubated with the peptide mixture at six concentrations from about 30 μM decreasing to about 0.05 μM .

Using the above described assay with the conditions of: the Test Compound A ranging from 0.05 to 3 mM, Test Compound A shows dose dependent inhibition of $A\beta_{1-42}$

oligomer assembly as shown in **FIG. 1**. Test Compound A appears as compound 4 of Table 1. Additionally, Test Compound B assayed at a concentration of 30 μ M shows only partial assembly inhibition at very high concentrations (**FIG. 1**). Examples of other compounds having a molecular weight of less than 1000 and requisite activity as tested in this assay are
5 found in Table 1.

Example 2

Comparative Example of Putative A β Assembly Blocker

Using the FRET assay described above, several compounds originally developed as amyloid fibril blockers were tested for blocking of A β ₁₋₄₂ monomer assembly into A β
10 oligomers. The compounds tested include, AlzhemedTM (Neurochem), scyllo-inositol also know as AZD-103 (Ellipsis), SP-235 (Samaritan), benzofurans (GE), 9-acridinones (Warner-Lambert), cyclodextrins (University of Illinois, Chicago), RS-406 (Sankyo), Clioquinol (Prana), and Curcumin (UCLA/UCI). Standard FRET assay conditions described in Example 1 were used. The inability of the compound Alzhemed to inhibit A β ₁₋₄₂
15 monomer assembly into A β oligomers is shown in **FIG 2**. These results are representative of all the compounds listed above, which were originally developed as amyloid fibril blockers.

Example 3

Alternating Lever Cyclic Ratio Rat Model

Preparations of A β ₁₋₄₂ ADDLs and a potential therapeutic compound under the
20 Alternating Lever Cyclic Ratio (ALCR) rat model of AD are tested to show *in vivo* efficacy. This highly sensitive model has been able to detect cognitive deficits due to direct injection of cell-derived A β oligomers into rat brain. Using this technique, a direct injection of ADDLs made from synthetic A β ₁₋₄₂ and a putative therapeutic compound under the ALCR
25 procedure may be tested.

The ALCR test has proven to be much more sensitive than previously published methods for measuring drug effects on cognitive function. In this task, rats must learn a complex sequence of lever-pressing requirements in order to earn food reinforcement in a two-lever experimental chamber. Subjects must alternate between two levers by switching
30 to the other lever after pressing the first lever enough to get food reward. The exact number of presses required for each food reward changes, first increasing from 2 responses per food

pellet up to 56 presses per food pellet, then decreasing back to 2 responses per pellet. Intermediate values are based on the quadratic function, $x^2 - x$. One cycle is an entire ascending and descending sequence of these lever press requirements (e.g., 2, 6, 12, 20, 30, 42, 56, 56, 42, 30, 20, 12, 6, and 2 presses per food reward). Six such full cycles are presented during each daily session. Errors are scored when the subject perseveres on a lever after pressing enough to get the food reward, i.e., does not alternate (a Perseveration Error), or when a subject switches levers before completing the response requirement on that lever (an Approach Error).

Materials and Methods

Synthetic $A\beta_{1-42}$ powder is dissolved in 1,1,1,3,3,3 hexafluoroisopropanol (HFIP) to afford a solution of $A\beta_{1-42}$ in HFIP of about 1 mM and allowed to incubate at ambient temperature for about 1 h. The resulting solution is chilled on ice for about 5-10 min, then aliquoted into eppendorf tubes to provide about 50 μ L of solution per tube. The tubes are then placed in a chemical fume hood and allowed to stand overnight to allow the HFIP to evaporate under a slow stream of nitrogen. To remove final traces of HFIP, the tubes are subjected to two SpeedVac cycles of 15 min at room temperature and about 15 to 25 mm Hg of vacuum. The resulting films of monomerized $A\beta_{1-42}$ peptide are stored over desiccant at -80 °C until used.

A tube of monomerized $A\beta_{1-42}$ peptide is warmed to room temperature and the $A\beta_{1-42}$ peptide is dissolved in anhydrous DMSO to afford a peptide stock DMSO solution containing about 10 μ M to about 100 μ M $A\beta_{1-42}$ peptide in DMSO.

2 μ L of a 20 mM stock solution of test compound in anhydrous DMSO is added to about 998 μ L of neural basal media (phenol red free, Gibco 12348-017) to give a compound neural basal media solution containing 40 μ M of test compound in neural basal media.

For the $A\beta_{1-42}$ peptide only treatment, peptide stock DMSO solution is added to 37 °C neural basal to obtain the requisite $A\beta_{1-42}$ peptide monomer concentration, provided that the maximum concentration of DMSO is 1% or less, and the tube is vortexed for 30 to 60 seconds, spun down briefly in a microfuge and incubated at 37 °C for 15 min prior to the start of injections.

For the A β ₁₋₄₂ peptide plus test compound treatment, peptide stock DMSO solution is added to 37 °C compound neural basal media solution to obtain the requisite A β ₁₋₄₂ peptide monomer concentration, provided that the maximum concentration of DMSO is 1% or less, and the tube is vortexed for 30 to 36 seconds, spun down briefly in a microfuge and
5 incubated at 37 °C for 15 min prior to the start of injections.

For control injections, compound neural basal media solution is incubated at 37 °C for 15 min prior to the start of injections.

Rats: Rats are trained under ALCR until their error rates are stable. Once the rats are placed upon the final ALCR procedure, training sessions are conducted 7 days each
10 week until the end of the study.

Surgery: All rats receive a single 28 ga cannula, which is permanently affixed to the skull, and aimed at the lateral ventricle. Half the rats receive cannula in the right ventricle and half receive cannula in the left ventricle. Rats are allowed 5 days to recover from surgery before training resumed.

15 Injection of Test Material and ALCR Testing: Test are conducted about every fourth day. Animals received a 20 μ L injection of control, peptide, or peptide plus compound solutions via the implanted cannula over about 3 to 4 minutes. Animals are tested about 3 hours following injection.

Error Rate Analysis: All error rates under will be compared to baseline error rates
20 consisting of at least 3 non-treatment days temporally contiguous to the injection. Student's T test of statistical inference was used for analysis of effects.

Contemplated Results

It is contemplated that a significant increase in Perseveration Error rate will be found between baseline error rates and error rates produced by A β ₁₋₄₂ ADDLs. It is also
25 contemplated that addition of one or more of the compounds described herein will not increase error rates when given alone, but when combined with the A β ₁₋₄₂ ADDLs, the compound(s) will eliminate the increase in Perseveration Errors. Thus, it is contemplated that at least one or more of the compounds described herein will rescued errors produced by A β ₁₋₄₂ ADDLs.

From the foregoing description, various modifications and changes in the compositions and methods will occur to those skilled in the art. All such modifications coming within the scope of the appended claims are intended to be included therein.

WHAT IS CLAIMED IS:

1. A method for antagonizing neurotoxic ADDL formation from monomeric $A\beta_{1-42}$ by contacting monomeric $A\beta_{1-42}$ with a substantially pure non-peptidic compound, said compound being characterized by:

- (a) having a molecular weight of less than 1000;
- (b) being an antagonist against formation of neurotoxic ADDLs from $A\beta_{1-42}$ monomers; and
- (c) exhibiting an IC_{50} of about 5 μ M or less in the assay of Example 1, which measures the formation of neurotoxic ADDLs.

2. A method of inhibiting, regulating and/or modulating the ADDL-induced neuronal dysfunction and/or neurotoxicity in a neuronal cell or neuronal tissue by inhibiting the formation of ADDLs which method comprises contacting $A\beta_{1-42}$ monomers which may be in the presence of a neuronal cell with an effective amount of a substantially pure non-peptidic compound, said compound being characterized by:

- (a) having a molecular weight of less than 1000;
- (b) being an antagonist against formation of neurotoxic ADDLs from $A\beta_{1-42}$ monomers; and
- (c) exhibiting an IC_{50} of about 5 μ M or less in the assay of Example 1, which measures the formation of neurotoxic ADDLs.

3. A method of inhibiting, regulating and/or modulating ADDL formation or the activity of such ligand in a patient suffering from or at risk of suffering from a disease associated with formation of amyloid- β oligomers, wherein said method comprises administering to said patient a therapeutically effective amount of a substantially pure non-peptidic compound, said compound being characterized by

- (a) having a molecular weight of less than 1000;
- (b) being an antagonist against formation of neurotoxic ADDLs from $A\beta_{1-42}$ monomers; and
- (c) exhibiting an IC_{50} of about 5 μ M or less in the assay of Example 1, which measures the formation of neurotoxic ADDLs.

4. The method according to any one of Claims 1-3, wherein said compound exhibits an inhibition in the formation of neurotoxic ADDLs as measured by an IC₅₀ of about 2 μM or less in the assay of Example 1.
5. The method of Claim 4, wherein said compound exhibits an inhibition in the formation of neurotoxic ADDLs as measured by an IC₅₀ of about 1 μM or less in the assay of Example 1.
6. The method of Claim 2, wherein said neuronal cells are isolated from animal brain tissue and grown in tissue culture.
7. The method of Claim 3, wherein the substantially pure non-peptidic compound is administered in the amount of from about 0.05 mg to about 1000 mg, one or more times per day.
8. The method of Claim 7, wherein the compound is administered in a pharmaceutical composition, further comprising a pharmaceutically acceptable excipient.
9. The method of Claim 3, wherein the disease is associated with insoluble amyloid fibrils, senile plaques, and/or tangles.
10. The method of Claim 3, wherein the disease is selected from the group consisting of Alzheimer's disease, Down's Syndrome, stroke and mild cognitive impairment.
11. The method of Claim 3, wherein disease is associated with over-expression of amyloid β₁₋₄₂ protein.
12. The method of Claim 3, wherein disease is selected from the group consisting of focal ischemia associated dementia and neuronal degeneration.
13. A method for treating a patient suffering from or at risk of suffering from a disease selected from the group consisting of Alzheimer's disease, Down's Syndrome, stroke, mild cognitive impairment, focal ischemia associated dementia, and neuronal degeneration comprising administering to said patient a therapeutically effective amount of a substantially pure non-peptidic compound, said compound being characterized by:

- (a) having a molecular weight of less than 1000;
- (b) being an antagonist against formation of neurotoxic ADDLs from A β ₁₋₄₂ monomers; and
- (c) exhibiting an IC₅₀ of about 5 μ M or less in the assay of Example 1, which measures the formation of neurotoxic ADDLs.

14. The method of Claim 13, wherein the substantially pure non-peptidic compound is administered in the range of from about 0.05 mg to about 1000 mg, one or more times per day.

15. The method of Claim 14, wherein the compound is administered in a pharmaceutical composition, further comprising a pharmaceutically acceptable excipient.

16. A composition for antagonizing neurotoxic ADDL formation from monomeric A β ₁₋₄₂ wherein the composition comprises an effective amount of a substantially pure non-peptidic compound, said compound characterized by:

- (a) having a molecular weight of less than 1000;
- (b) being an antagonist against formation of neurotoxic ADDLs from A β ₁₋₄₂ monomers; and
- (c) exhibiting an IC₅₀ of about 5 μ M or less in the assay of Example 1, which measures the formation of neurotoxic ADDLs.

17. A composition for inhibiting, regulating or modulating any ADDL-induced neuronal dysfunction or neurotoxicity in a neuronal cell by inhibiting the formation of ADDLs, wherein the composition comprises an effective amount of a substantially pure non-peptidic compound, said compound characterized by:

- (a) having a molecular weight of less than 1000;
- (b) being an antagonist against formation of neurotoxic ADDLs from A β ₁₋₄₂ monomers; and
- (c) exhibiting an IC₅₀ of about 5 μ M or less in the assay of Example 1, which measures the formation of neurotoxic ADDLs.

18. The composition of claim 16 or 17, wherein said compound exhibits an inhibition in the formation of neurotoxic ADDLs as measured by an IC₅₀ of about 2 μ M or less in the assay of Example 1.

19. The composition of claim 16 or 17, wherein said compound exhibits an inhibition in the formation of neurotoxic ADDLs as measured by an IC_{50} of about 1 μ M or less in an assay of Example 1.

20. The composition of claim 16 or 17, wherein the substantially pure non-peptidic compound is administered in the amount of from about 0.05 mg to about 1000 mg, one or more times per day.

21. The composition of claim 16 or 17, wherein the compound further comprises a pharmaceutically acceptable excipient.

22. The composition of claim 16 or 17, wherein the ADDL, if any, is associated with insoluble amyloid fibrils, senile plaques, or tangles.

23. The composition of claim 16 or 17, wherein the ADDL, if any, is associated with a disease selected from the group consisting of Alzheimer's disease, Down's Syndrome, stroke and mild cognitive impairment.

24. The composition of claim 16 or 17, wherein the ADDL, if any, is associated with a disease selected from the group consisting of focal ischemia associated dementia and neuronal degeneration.

25. The composition of claim 16 or 17, wherein the ADDL, if any, is associated with over-expression of amyloid β_{1-42} protein.

26. The composition of claim 17 wherein said neuronal cell is isolated from animal brain tissue and grown in tissue culture.

27. The composition of claim 16 or 17, wherein the composition further comprises a pharmaceutically acceptable excipient.




FIG.1




FIG. 2




FIG.1